UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Advances in understanding prognosis in myeloma

Smith, D; Yong, K; (2016) Advances in understanding prognosis in myeloma. British Journal of Haematology , 175 (3) pp. 367-380. 10.1111/bjh.14304. Green open access

[thumbnail of Yong_AAM_prognosis review changes after reviewers comments 24 april DS.pdf]
Preview
Text
Yong_AAM_prognosis review changes after reviewers comments 24 april DS.pdf - Accepted Version

Download (986kB) | Preview

Abstract

In the last two decades outcomes in multiple myeloma (myeloma) have greatly improved, due to the introduction of newer, more effective therapies. This improvement is not uniform. Response to treatment and survival remains heterogeneous, with some patients living for 1–2 years whilst others are alive and progression‐free at 10 years. This variation in outcome is due to patient characteristics plus features intrinsic to the myeloma tumour. Alongside the introduction of novel therapies there has been a greater understanding of disease biology and mechanisms of resistance. This has led to an increase in the number of prognostic markers that can be used in myeloma. This is important not only for more accurate counselling of patients in terms of disease outcome, but also in paving the way for risk‐adapted therapy. Both newer and traditional prognostic markers need to be used in the context of planned therapy. Indeed, the prognostic value of certain markers varies according to which therapy the patient receives. As such, these prognostic factors will require constant re‐evaluation as agents with new mechanisms of action are added into the myeloma treatment algorithm. This article summarises current concepts of prognostic markers in myeloma.

Type: Article
Title: Advances in understanding prognosis in myeloma
Open access status: An open access version is available from UCL Discovery
DOI: 10.1111/bjh.14304
Publisher version: https://doi.org/10.1111/bjh.14304
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: multiple myeloma, prognostic factors, myeloma therapy
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: https://discovery.ucl.ac.uk/id/eprint/10081289
Downloads since deposit
449Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item